Actos Generics Should Await Expiration Of All Patented Uses, Takeda Tells FDA
Executive Summary
Approving generic versions of Takeda's Actos for use as monotherapy prior to expiration of its combination-use patents would hinder the safe and effective use of the diabetes drug, the firm says in a petition to FDA